PF-05221304 Monotherapy + PF-06865571 Monotherapy + Placebo + PF-05221304 and PF-06865571 Combination
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Alcoholic Fatty Liver Disease (NAFLD)
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD)
Trial Timeline
Jan 4, 2019 → Oct 11, 2019
NCT ID
NCT03776175About PF-05221304 Monotherapy + PF-06865571 Monotherapy + Placebo + PF-05221304 and PF-06865571 Combination
PF-05221304 Monotherapy + PF-06865571 Monotherapy + Placebo + PF-05221304 and PF-06865571 Combination is a phase 2 stage product being developed by Pfizer for Non-Alcoholic Fatty Liver Disease (NAFLD). The current trial status is completed. This product is registered under clinical trial identifier NCT03776175. Target conditions include Non-Alcoholic Fatty Liver Disease (NAFLD).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03776175 | Phase 2 | Completed |
Competing Products
20 competing products in Non-Alcoholic Fatty Liver Disease (NAFLD)